Skip to main content Accessibility help
×
Hostname: page-component-848d4c4894-x5gtn Total loading time: 0 Render date: 2024-05-16T18:26:44.133Z Has data issue: false hasContentIssue false

33 - Emerging roles of peroxisome proliferator-activated receptor gamma in cancer

from Part 2.3 - Molecular pathways underlying carcinogenesis: nuclear receptors

Published online by Cambridge University Press:  05 February 2015

Chenguang Wang
Affiliation:
Department of Stem Cell Biology and Regenerative Medicine, Kimmel Cancer Center, Thomas Jeferson University, Philadelphia, PA, USA
Xuemin Zhang
Affiliation:
State Key Laboratory of Proteomics, Institute of Basic Medical Sciences, National Center of Biomedical Analysis, Beijing, China
Lifeng Tian
Affiliation:
Department of Cancer Biology, Kimmel Cancer Center, Thomas Jeferson University, Philadelphia, PA, USA
Richard G. Pestell
Affiliation:
Department of Cancer Biology, Kimmel Cancer Center, Thomas Jeferson University, Philadelphia, PA, USA
Edward P. Gelmann
Affiliation:
Columbia University, New York
Charles L. Sawyers
Affiliation:
Memorial Sloan-Kettering Cancer Center, New York
Frank J. Rauscher, III
Affiliation:
The Wistar Institute Cancer Centre, Philadelphia
Get access

Summary

Focus

The peroxisome proliferator-activated receptors (PPARs) are ligand-activated nuclear receptors, which include PPARα, PPARγ, and PPARδ (1). PPARγ was initially cloned as a transcription factor involved in adipocyte differentiation. Subsequent studies suggested a broad spectrum of PPARγ functions in lipid metabolism, inflammation, atherogenesis, and cell differentiation, as well as in tumorigenesis. Herein, we review recent studies suggesting a dominant role for PPARγ in processes related to cancer initiation and progression, and describe the mechanisms by which PPARγ regulates cell-cycle progression, cell death, and angiogenesis.

Structural features of PPARγ

There are three PPARγ isoforms (γ1, γ2, and γ3). Both PPARγ1 and PPARγ2 are abundantly expressed in adipose tissue, whereas PPARγ1 expression is detected in liver, spleen, heart tissues, and epithelium of a variety of tissues including breast and prostate. Their modular structure resembles other nuclear hormone receptors with an N-terminal activation function 1 (AF-1), a DNA-binding domain (DBD), and a C-terminal ligand-binding domain (activation function 2, AF-2).

Type
Chapter
Information
Molecular Oncology
Causes of Cancer and Targets for Treatment
, pp. 392 - 402
Publisher: Cambridge University Press
Print publication year: 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Rosen, ED, Spiegelman, BM.PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth. Journal of Biological Chemistry 2001;276:37 731–4.CrossRefGoogle ScholarPubMed
Kim, JB, Spiegelman, BM. ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. Genes and Development 1996;10:1096–107.CrossRef
Kim, JB, Wright, HM, Wright, M, Spiegelman, BM. ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand. Proceedings of the National Academy of Sciences USA 1998;95:4333–7.CrossRef
Spiegelman, BM, Hu, E, Kim, JB, Brun, R. PPAR gamma and the control of adipogenesis. Biochimie 1997;79:111–12.CrossRef
Deeb, SS, Fajas, L, Nemoto, M, et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nature Genetics 1998;20:284–7.CrossRef
Smith, WM, Zhou, XP, Kurose, K, et al. Opposite association of two PPARG variants with cancer: overrepresentation of H449H in endometrial carcinoma cases and underrepresentation of P12A in renal cell carcinoma cases. Human Genetics 2001;109:146–51.CrossRef
Sarraf, P, Mueller, E, Smith, WM, et al. Loss-of-function mutations in PPAR gamma associated with human colon cancer. Molecular Cell 1999;3:799–804.CrossRef
Shoff, SM, Newcomb, PA.Diabetes, body size, and risk of endometrial cancer. American Journal of Epidemiology 1998;148:234–40.CrossRefGoogle ScholarPubMed
Gull, B, Karlsson, B, Milsom, I, Granberg, S.Factors associated with endometrial thickness and uterine size in a random sample of postmenopausal women. American Journal of Obstetrics and Gynecology 2001;185:386–91.CrossRefGoogle Scholar
Bergstrom, A, Hsieh, CC, Lindblad, P, et al. Obesity and renal cell cancer–a quantitative review. British Journal of Cancer 2001;85:984–90.CrossRefGoogle ScholarPubMed
Chow, WH, Gridley, G, Fraumeni, JF, Obesity, Jarvholm B., hypertension, and the risk of kidney cancer in men. New England Journal of Medicine. 2000;343:1305–11.CrossRefGoogle ScholarPubMed
McLaughlin, JK, Lipworth, L. Epidemiologic aspects of renal cell cancer. Seminars on Oncology 2000;27:115–23.
Cheung, L, Messina, M, Gill, A, et al. Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas. Journal of Clinical Endocrinology and Metabolism 2003;88:354–7.CrossRefGoogle ScholarPubMed
Kroll, TG, Sarraf, P, Pecciarini, L, et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science 2000;289:1357–60.CrossRef
Au, AY, McBride, C, Wilhelm, KG, et al. PAX8-peroxisome proliferator-activated receptor gamma (PPARgamma) disrupts normal PAX8 or PPARgamma transcriptional function and stimulates follicular thyroid cell growth. Endocrinology 2006;147:367–76.CrossRef
Hu, E, Kim, JB, Sarraf, P, Spiegelman BM. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma. Science 1996;274:2100–3.CrossRef
Adams, M, Reginato, MJ, Shao, D, Lazar, MA, Chatterjee, VK.Transcriptional activation by PPARγ is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. Journal of Biological Chemistry 1997;272: 5128–32.CrossRefGoogle Scholar
Camp, HS, Tafuri, SR.Regulation of peroxisome proliferator-activated receptor gamma activity by mitogen-activated protein kinase. Journal of Biological Chemistry 1997;272:10 811–6.CrossRefGoogle ScholarPubMed
Camp, HS, Tafuri, SR, Leff, T. c-Jun N-terminal kinase phosphorylates peroxisome proliferator-activated receptor-gamma1 and negatively regulates its transcriptional activity. Endocrinology 1999;140:392–7.CrossRef
Floyd, ZE, Stephens, JM.Interferon-gamma-mediated activation and ubiquitin-proteasome-dependent degradation of PPARgamma in adipocytes. Journal of Biological Chemistry 2002;277:4062–8.CrossRefGoogle ScholarPubMed
Floyd, ZE, Wang, ZQ, Kilroy, G, Cefalu, WT. Modulation of peroxisome proliferator-activated receptor gamma stability and transcriptional activity in adipocytes by resveratrol. Metabolism 2008;57:S32–8.
Hauser, S, Adelmant, G, Sarraf, P, et al. Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation. Journal of Biological Chemistry 2000;275:18 527–33.CrossRefGoogle ScholarPubMed
Kilroy, GE, Zhang, X, Floyd, ZE. PPAR-gamma AF-2 domain functions as a component of a ubiquitin-dependent degradation signal. Obesity (Silver Spring). 2009;17:665–73.CrossRef
Jennewein, C, Kuhn, AM, Schmidt, MV, et al. Sumoylation of peroxisome proliferator-activated receptor gamma by apoptotic cells prevents lipopolysaccharide-induced NCoR removal from kappaB binding sites mediating transrepression of proinflammatory cytokines. Journal of Immunology 2008;181:5646–52.CrossRefGoogle ScholarPubMed
Ghisletti, S, Huang, W, Ogawa, S, et al. Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgamma. Molecular Cell 2007;25:57–70.CrossRef
Pascual, G, Fong, AL, Ogawa, S, et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005;437:759–63.CrossRef
Ohshima, T, Koga, H, Shimotohno, K.Transcriptional activity of peroxisome proliferator-activated receptor gamma is modulated by SUMO-1 modification. Journal of Biological Chemistry 2004;279:29 551–7.CrossRefGoogle ScholarPubMed
Fu, M, Wang, J, Wang, C, Pestell, RG. Acetylation sites govern PKA-dependent androgen receptor function. Proceedings of the American Association for Cancer Research 2001;42:250.
Wang, C, Fu, M, Angeletti, RH, et al. Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity. Journal of Biological Chemistry 2001;276:18 375–83.CrossRefGoogle ScholarPubMed
Picard, F, Kurtev, M, Chung, N, et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 2004;429:771–6.CrossRef
Bouras, T, Fu, M, Sauve, AA, et al. SIRT1 deacetylation and repression of P300 involves lysine residues 1020/1024 within the cell-cycle regulatory domain 1. Journal of Biological Chemistry 2005;280:10 264–76.CrossRefGoogle ScholarPubMed
Wang, C, Fu, M, D’Amico, M, et al. Inhibition of cellular proliferation through IkappaB kinase-independent and peroxisome proliferator-activated receptor gamma-dependent repression of cyclin D1. Molecular and Cellular Biology 2001;21:3057–70.CrossRef
Nielsen, R, Pedersen, TA, Hagenbeek, D, et al. Genome-wide profiling of PPARgamma:RXR and RNA polymerase II occupancy reveals temporal activation of distinct metabolic pathways and changes in RXR dimer composition during adipogenesis. Genes and Development 2008;22:2953–67.CrossRef
Wang, LH, Yang, XY, Zhang, X, Farrar, WL. Inhibition of adhesive interaction between multiple myeloma and bone marrow stromal cells by PPARgamma cross talk with NF-kappaB and C/EBP. Blood 2007;110:4373–84.CrossRef
Tomita, K, Hanafusa, T. [PPARs, cancer cells and inflammation]. Nippon Rinsho 2000;58:461–4.
Wang, C, Pattabiraman, N, Zhou, JN, et al. Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation. Molecular and Cellular Biology 2003;23:6159–73.CrossRef
Tontonoz, P, Hu, E, Spiegelman, BM. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 1994;79:1147–56.CrossRef
Yu, S, Matsusue, K, Kashireddy, P, et al. Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor 1 (PPAR1) overexpression. Journal of Biological Chemistry 2003;278: 498–505.CrossRefGoogle Scholar
Kubota, N, Terauchi, Y, Miki, H, et al. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Molecular Cell 1999;4:597–609.CrossRef
Rosen, ED, Sarraf, P, Troy, AE, et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Molecular Cell 1999;4:611–17.CrossRef
Teruel, T, Hernandez, R, Rial, E, Martin-Hidalgo, A, Lorenzo, M. Rosiglitazone up-regulates lipoprotein lipase, hormone-sensitive lipase and uncoupling protein-1, and down-regulates insulin-induced fatty acid synthase gene expression in brown adipocytes of Wistar rats. Diabetologia 2005;48:1180–8.CrossRef
Watkins, SM, Reifsnyder, PR, Pan, HJ, German, JB, Leiter, EH.Lipid metabolome-wide effects of the PPARgamma agonist rosiglitazone. Journal of Lipid Research 2002;43:1809–17.CrossRefGoogle ScholarPubMed
Poritsanos, NJ, Wong, D, Vrontakis, ME, Mizuno, TM. Regulation of hepatic PPARgamma2 and lipogenic gene expression by melanocortin. Biochemical and Biophysical Research Communications 2008;376:384–8.CrossRef
Schroeder-Gloeckler, JM, Rahman, SM, Janssen, RC, et al. CCAAT/enhancer-binding protein beta deletion reduces adiposity, hepatic steatosis, and diabetes in Lepr(db/db) mice. Journal of Biological Chemistry 2007;282:15 717–29.CrossRefGoogle ScholarPubMed
Fu, M, Rao, M, Bouras, T, et al. Recruitment of HDACs by Cyclin D1 inhibits PPAR-gama mediated adipogenesis. Journal of Biological Chemistry 2004;279:24 745–56.Google Scholar
Zhou, J, Zhang, W, Liang, B, et al. PPARgamma activation induces autophagy in breast cancer cells. International Journal of Biochemistry and Cell Biology 2009;41:2334–42.CrossRefGoogle ScholarPubMed
Yin, R, Dong, YG, Li, HL. PPARgamma phosphorylation mediated by JNK MAPK: a potential role in macrophage-derived foam cell formation. Acta Pharmacologica Sinica 2006;27:1146–52.CrossRef
Schild, RL, Sonnenberg-Hirche, CM, Schaiff, WT, et al. The kinase p38 regulates peroxisome proliferator activated receptor-gamma in human trophoblasts. Placenta 2006;27:191–9.CrossRef
Harrington, M, Pond-Tor, S, Boney, CM. Role of epidermal growth factor and ERBB2 receptors in 3T3-L1 adipogenesis. Obesity (Silver Spring) 2007;15:563–71.CrossRef
Fu, M, Zhu, X, Wang, Q, et al. Platelet-derived growth factor promotes the expression of peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells by a phosphatidylinositol 3-kinase/Akt signaling pathway. Circulation Research 2001;89:1058–64.CrossRef
Kortum, RL, Costanzo, DL, Haferbier, J, et al. The molecular scaffold kinase suppressor of Ras 1 (KSR1) regulates adipogenesis. Molecular and Cellular Biology 2005;25:7592–604.CrossRef
Fu, M, Wang, C, Li, Z, Sakamaki, T, Pestell, RG. Minireview: cyclin D1: normal and abnormal functions. Endocrinology 2004;145:5439–47.CrossRef
Fu, M, Rao, M, Bouras, T, et al. Cyclin D1 inhibits peroxisome proliferator-activated receptor gamma-mediated adipogenesis through histone deacetylase recruitment. Journal of Biological Chemistry 2005;280:16 934–41.CrossRefGoogle ScholarPubMed
Fu, M, Wang, C, Rao, M, et al. Cyclin D1 represses p300 transactivation through a cyclin-dependent kinase-independent mechanism. Journal of Biological Chemistry 2005;280:29 728–42.CrossRefGoogle ScholarPubMed
McMahon, C, Suthiphongchai, T, DiRenzo, J, Ewen, ME. P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor. Proceedings of the National Academy of Sciences USA 1999;96:5382–7.CrossRef
Reutens, AT, Fu, M, Wang, C, et al. Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner. Molecular Endocrinology 2001;15:797–811.CrossRef
Petre-Draviam, CE, Williams, EB, Burd, CJ, et al. A central domain of cyclin D1 mediates nuclear receptor corepressor activity. Oncogene 2005;24:431–44.CrossRef
Zwijsen, RM, Wientjens, E, Klompmaker, R, et al. CDK-independent activation of estrogen receptor by cyclin D1. Cell 1997;88:405–15.CrossRef
Neuman, E, Ladha, MH, Lin, N, et al. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Molecular and Cellular Biology 1997;17:5338–47.CrossRef
Schadinger, SE, Bucher, NL, Schreiber, BM, Farmer, SR.PPARgamma2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes. American Journal of Physiology, Endocrinology and Metabolism 2005;288:E1195–205.CrossRefGoogle ScholarPubMed
Zhang, YL, Hernandez-Ono, A, Siri, P, et al. Aberrant hepatic expression of PPARgamma2 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslipidemia, and hepatic steatosis. Journal of Biological Chemistry 2006;281:37 603–15.CrossRefGoogle Scholar
Albanese, C, Wu, K, D’Amico, M, et al. IKKalpha regulates mitogenic signaling through transcriptional induction of cyclin D1 via Tcf. Molecular Biology of the Cell 2003;14:585–99.CrossRef
Lee, RJ, Albanese, C, Fu, M, et al. Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Molecular and Cellular Biology 2000;20:672–83.CrossRef
Lee, RJ, Albanese, C, Stenger, RJ, et al. pp60(v-src) induction of cyclin D1 requires collaborative interactions between the extracellular signal-regulated kinase, p38, and Jun kinase pathways. A role for cAMP response element-binding protein and activating transcription factor-2 in pp60(v-src) signaling in breast cancer cells. Journal of Biological Chemistry 1999;274:7341–50.CrossRefGoogle ScholarPubMed
Watanabe, G, Howe, A, Lee, RJ, et al. Induction of cyclin D1 by simian virus 40 small tumor antigen. Proceedings of the National Academy of Sciences USA 1996;93:12 861–6.
Albanese, C, Johnson, J, Watanabe, G, et al. Transforming p21 mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. Journal of Biological Chemistry 1995;270:23 589–97.CrossRef
Saez, E, Rosenfeld, J, Livolsi, A, et al. PPAR gamma signaling exacerbates mammary gland tumor development. Genes and Development 2004;18:528–40.CrossRef
Tian, L, Zhou, J, Casimiro, MC, et al. Activating peroxisome proliferator-activated receptor gamma mutant promotes tumor growth in vivo by enhancing angiogenesis. Cancer Research 2009;69:9236–44.CrossRef
Zhou, J, Zhang, W, Liang, B, et al. PPARgamma activation induces autophagy in breast cancer cells. International Journal of Biochemistry and Cell Biology 2009;41:2334–42.CrossRefGoogle ScholarPubMed
Brockman, JA, Gupta, RA, Dubois, RN. Activation of PPARgamma leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology 1998;115:1049–55.CrossRef
Coopman, PJ, Do, MT, Thompson, EW, Mueller, SC. Phagocytosis of cross-linked gelatin matrix by human breast carcinoma cells correlates with their invasive capacity. Clinical Cancer Research 1998;4:507–15.
Elstner, E, Muller, C, Koshizuka, K, et al. Ligands for peroxisome proliferator-activated receptorγ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proceedings of the National Academy of Sciences USA 1998;95:8806–11.CrossRef
Ricote, M, Huang, J, Fajas, L, et al. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proceedings of the National Academy of Sciences USA 1998;95:7614–19.CrossRef
Sarraf, P, Mueller, E, Jones, D, et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nature Medicine 1998;4:1046–52.CrossRef
Lu, M, Kwan, T, Yu, C, et al. Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest. Journal of Biological Chemistry 2005;280:6742–51.CrossRefGoogle ScholarPubMed
Hulit, J, Wang, C, Li, Z, et al. Cyclin D1 genetic heterozygosity regulates colonic epithelial cell differentiation and tumor number in ApcMin mice. Molecular and Cellular Biology 2004;24:7598–611.CrossRef
Pighetti, GM, Novosad, W, Nicholson, C, et al. Therapeutic treatment of DMBA-induced mammary tumors with PPAR ligands. Anticancer Research. 2001;21:825–9.
Saez, E, Tontonoz, P, Nelson, MC, et al. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nature Medicine 1998;4:1058–61.CrossRef
Kitamura, S, Miyazaki, Y, Shinomura, Y, et al. Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells. Japanese Journal of Cancer Research 1999;90:75–80.CrossRefGoogle ScholarPubMed
DuBois, RN, Gupta, R, Brockman, J, et al. The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers. Carcinogenesis 1998;19:49–53.CrossRef
Dai, Y, Qiao, L, Chan, KW, et al. Loss of XIAP sensitizes rosiglitazone-induced growth inhibition of colon cancer in vivo. International Journal of Cancer 2008;122:2858–63.CrossRefGoogle ScholarPubMed
Lefebvre, AM, Chen, I, Desreumaux, P, et al. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nature Medicine 1998;4:1053–7.CrossRef
Ota, K, Ito, K, Suzuki, T, et al. Peroxisome proliferator-activated receptor gamma and growth inhibition by its ligands in uterine endometrial carcinoma. Clinical Cancer Research 2006;12:4200–8.CrossRef
Wu, Y, Guo, SW. Peroxisome proliferator-activated receptor-gamma and retinoid X receptor agonists synergistically suppress proliferation of immortalized endometrial stromal cells. Fertility and Sterility 2009;91:2142–7.CrossRef
Wu, W, Celestino, J, Milam, MR, et al. Primary chemoprevention of endometrial hyperplasia with the peroxisome proliferator-activated receptor gamma agonist rosiglitazone in the PTEN heterozygote murine model. International Journal of Gynecological Cancer 2008;18:329–38.CrossRefGoogle ScholarPubMed
Elstner, E, Muller, C, Koshizuka, K, et al. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proceedings of the National Academy of Sciences USA 1998;95:8806–11.CrossRef
Clay, CE, Namen, AM, Atsumi, G, et al. Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. Carcinogenesis 1999;20:1905–11.CrossRef
Nwankwo, JO, Robbins, ME. Peroxisome proliferator-activated receptor- gamma expression in human malignant and normal brain, breast and prostate-derived cells. Prostaglandins, Leukotrienes and Essential Fatty Acids 2001;64:241–5.CrossRef
Martelli, ML, Iuliano, R, Le Pera, I, et al. Inhibitory effects of peroxisome poliferator-activated receptor gamma on thyroid carcinoma cell growth. Journal of Clinical Endocrinology and Metabolism 2002;87:4728–35.CrossRefGoogle ScholarPubMed
Shimada, T, Kojima, K, Yoshiura, K, Hiraishi, H, Terano, A. Characteristics of the peroxisome proliferator activated receptor gamma (PPARgamma) ligand induced apoptosis in colon cancer cells. Gut 2002;50:658–64.CrossRef
Toyoda, M, Takagi, H, Horiguchi, N, et al. A ligand for peroxisome proliferator activated receptor gamma inhibits cell growth and induces apoptosis in human liver cancer cells. Gut 2002;50:563–7.CrossRef
Wang, YL, Frauwirth, KA, Rangwala, SM, Lazar, MA, Thompson, CB.Thiazolidinedione activation of peroxisome proliferator-activated receptor gamma can enhance mitochondrial potential and promote cell survival. Journal of Biological Chemistry 2002;277:31 781–8.CrossRefGoogle ScholarPubMed
Yoshizawa, K, Cioca, DP, Kawa, S, Tanaka, E, Kiyosawa, K. Peroxisome proliferator-activated receptor gamma ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines. Cancer 2002;95:2243–51.CrossRef
Debnath, J, Mills, KR, Collins, NL, et al. The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. Cell 2002;111:29–40.CrossRef
Muthuswamy, SK, Li, D, Lelievre, S, Bissell, MJ, Brugge, JS. ERBB2, but not ERBB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nature Cell Biology 2001;3:785–92.CrossRef
Debnath, J, Muthuswamy, SK, Brugge, JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003;30:256–68.CrossRef
Chawla, A, Barak, Y, Nagy, L, et al. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nature Medicine 2001;7:48–52.CrossRef
Clay, CE, Monjazeb, A, Thorburn, J, Chilton, FH, High, KP.15-Deoxy-Delta(12,14)-prostaglandin J(2)-induced apoptosis does not require PPARgamma in breast cancer cells. Journal of Lipid Research 2002;43:1818–28.CrossRefGoogle Scholar
Peraza, MA, Burdick, AD, Marin, HE, Gonzalez, FJ, Peters, JM. The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). Toxicological Sciences 2006;90:269–95.CrossRef
Pignatelli, M, Cortes-Canteli, M, Lai, C, Santos, A, Perez-Castillo, A.The peroxisome proliferator-activated receptor gamma is an inhibitor of ERBBs activity in human breast cancer cells. Journal of Cell Science 2001;114:4117–26.Google ScholarPubMed
Yu, HN, Lee, YR, Noh, EM, et al. Induction of G1 phase arrest and apoptosis in MDA-MB-231 breast cancer cells by troglitazone, a synthetic peroxisome proliferator-activated receptor gamma (PPARgamma) ligand. Cell Biology International 2008;32:906–12.CrossRef
Mody, M, Dharker, N, Bloomston, M, et al. Rosiglitazone sensitizes MDA-MB-231 breast cancer cells to anti-tumour effects of tumour necrosis factor-alpha, CH11 and CYC202. Endocrine Related Cancer 2007;14:305–15.CrossRef
Suh, N, Wang, Y, Williams, CR, et al. A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis. Cancer Research 1999;59:5671–3.
Mehta, RG, Williamson, E, Patel, MK, Koeffler, HP.A ligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions. Journal of the National Cancer Institute 2000;92:418–23.CrossRefGoogle ScholarPubMed
Nicol, CJ, Yoon, M, Ward, JM, et al. PPARgamma influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis. Carcinogenesis 2004;25:1747–55.CrossRef
Kroll, TG, Sarraf, P, Pecciarini, L, et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma. Science 2000;289:1357–60.CrossRef
Giaginis, C, Margeli, A, Theocharis, S. Peroxisome proliferator-activated receptor-gamma ligands as investigational modulators of angiogenesis. Expert Opinion on Investigational Drugs 2007;16:1561–72.CrossRef
Xin, X, Yang, S, Kowalski, J, Gerritsen, ME.Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. Journal of Biological Chemistry 1999;274:9116–21.CrossRefGoogle ScholarPubMed
Aljada, A, O’Connor, L, Fu, YY, Mousa, SA. PPAR gamma ligands, rosiglitazone and pioglitazone, inhibit bFGF- and VEGF-mediated angiogenesis. Angiogenesis 2008;11:361–7.CrossRef
Yamakawa, K, Hosoi, M, Koyama, H, et al. Peroxisome proliferator-activated receptor-gamma agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells. Biochemical and Biophysical Research Communications 2000;271:571–4.CrossRef
Chintalgattu, V, Harris, GS, Akula, SM, Katwa, LC. PPAR-gamma agonists induce the expression of VEGF and its receptors in cultured cardiac myofibroblasts. Cardiovascular Research 2007;74:140–50.CrossRef
Hermann, LM, Pinkerton, M, Jennings, K, et al. Angiopoietin-like-4 is a potential angiogenic mediator in arthritis. Clinical Immunology 2005;115:93–101.CrossRef
Le Jan, S, Amy, C, Cazes, A, et al. Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma. American Journal of Pathology 2003;162:1521–8.CrossRefGoogle ScholarPubMed
Gealekman, O, Burkart, A, Chouinard, M, et al. Enhanced angiogenesis in obesity and in response to PPARgamma activators through adipocyte VEGF and ANGPTL4 production. American Journal of Physiology, Endocrinology and Metabolism 2008;295:E1056–64.CrossRefGoogle ScholarPubMed
Magenta, G, Borenstein, X, Rolando, R, Jasnis, MA. Rosiglitazone inhibits metastasis development of a murine mammary tumor cell line LMM3. BMC Cancer 2008;8:47.CrossRef
Yoshizumi, T, Ohta, T, Ninomiya, I, et al. Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects. International Journal of Oncology 2004;25:631–9.Google ScholarPubMed
He, Q, Chen, J, Lin, HL, Hu, PJ, Chen, MH. Expression of peroxisome proliferator-activated receptor gamma, E-cadherin and matrix metalloproteinases-2 in gastric carcinoma and lymph node metastases. Chinese Medical Journal (Engl). 2007;120:1498–504.
Shen, D, Deng, C, Zhang, M. Peroxisome proliferator-activated receptor gamma agonists inhibit the proliferation and invasion of human colon cancer cells. Postgraduate Medical Journal 2007;83:414–19.CrossRef
Liu, H, Zang, C, Fenner, MH, Possinger, K, Elstner, E. PPARgamma ligands and ATRA inhibit the invasion of human breast cancer cells in vitro. Breast Cancer Research and Treatment 2003;79:63–74.CrossRef
Sunami, E, Tsuno, NH, Kitayama, J, et al. Decreased synthesis of matrix metalloproteinase-7 and adhesion to the extracellular matrix proteins of human colon cancer cells treated with troglitazone. Surgery Today 2002;32:343–50.CrossRef
Nakajima, A, Tomimoto, A, Fujita, K, et al. Inhibition of peroxisome proliferator-activated receptor gamma activity suppresses pancreatic cancer cell motility. Cancer Science 2008;99:1892–900.CrossRef
Padua, D, Zhang, XH, Wang, Q, et al. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 2008;133:66–77.CrossRef
Sporn, MB, Suh, N, Mangelsdorf, DJ. Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs). Trends in Molecular Medicine 2001;7:395–400.CrossRef
Demetri, GD, Fletcher, CD, Mueller, E, et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proceedings of the National Academy of Sciences USA 1999;96:3951–6.CrossRef
Debrock, G, Vanhentenrijk, V, Sciot, R, et al. A Phase II trial with rosiglitazone in liposarcoma patients. British Journal of Cancer 2003;89:1409–12.CrossRefGoogle ScholarPubMed
Burstein, HJ, Demetri, GD, Mueller, E, et al. Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a Phase II study. Breast Cancer Research and Treatment 2003;79:391–7.CrossRef
Girnun, GD, Chen, L, Silvaggi, J, et al. Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. Clinical Cancer Research 2008;14:6478–86.CrossRef
Girnun, GD, Naseri, E, Vafai, SB, et al. Synergy between PPARgamma ligands and platinum-based drugs in cancer. Cancer Cell 2007;11:395–406.CrossRef
Carew, JS, Nawrocki, ST, Kahue, CN, et al. Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood 2007;110:313–22.CrossRef

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×